Siemens Medical Systems, Epix Medical, and Mallinckrodt are teaming up to develop contrast-based cardiovascular MR imaging technologies to improve the diagnosis of atherosclerosis and related diseases. The collaboration will combine Epix and
Siemens Medical Systems, Epix Medical, and Mallinckrodt are teaming up to develop contrast-based cardiovascular MR imaging technologies to improve the diagnosis of atherosclerosis and related diseases. The collaboration will combine Epix and Mallinckrodts AngioMark intravascular MRI contrast agent with advanced imaging and 3-D visualization technologies to create enhanced MRI scanning protocols and imaging methods, according to the firms.
AngioMark is currently in a phase III clinical trial to determine the efficacy of the agent in detecting aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease or abdominal aortic aneurysm. The trial is designed to compare the diagnostic accuracy of AngioMark-enhanced MR angiography with x-ray angiography.
The nonexclusive collaboration between Siemens of Iselin, NJ, Cambridge, MA-based Epix, and Mallinckrodt of St. Louis will also focus on expanding the use of MRI in diagnosing cardiovascular disease and providing new tools to improve 3-D visualization of the cardiovascular system. Research and development will take place at both Siemens and Epix.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.